An open label randomised controlled trial to compare the effectiveness of subcutaneous Injection Adalimumab with intra-articular triamcinolone in primary knee osteoarthritis.

The proposed trial is phase 3 open label randomised control trial to compare the efficacy of subcutaneous inj. Adalimumab in comparison to an established therapy of intraarticular Inj. Triamcinolone for symptomatic primary Knee osteoarthritis with evidence of inflammation (clinical/biochemical/radiological). it is a superiority trial. The study will have two arms. each arm will have 37 patients each. after recruitment each patient will undergo contrast MRI of the involved joint to assess the baseline damage and activity in the involved joint. The intervention arm will receive monthly Inj. Adalimumab 40 mg for 3 months and the comparator arm will receive single dose of Intraarticular Triamcinolone. patients will be followed for primary outcome at 12 weeks.